Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combinatorial therapy

a conjugate therapy and vegf technology, applied in the field of conjugate therapy, can solve the problems that many patients treated with vegf antagonists eventually succumb to their disease, and achieve the effects of reducing or preventing antibody dependent cellular cytotoxicity (adcc) or complement dependent cytotoxicity (cdc) activity, improving effector function, and reducing or preventing antibody dependent cellular cytotoxicity (adcc) or cdc activity

Inactive Publication Date: 2009-09-03
GENENTECH INC
View PDF43 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods for inhibiting angiogenesis and vascular permeability in subjects who need it, such as patients with abnormal angiogenesis, neoplasms, and autoimmune diseases. The methods involve administering a combination of a VEGF antagonist and an alpha5beta1 antagonist either concurrently or sequentially. The invention also provides new anti-alpha5beta1 antibodies that can be used in these methods. The technical effects of the invention include improved treatment outcomes for patients with abnormal angiogenesis, reduced resistance to treatment, and improved detection of alpha5beta1 in patients.

Problems solved by technology

Despite these advances, many patients treated with VEGF antagonists eventually succumb to their disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinatorial therapy
  • Combinatorial therapy
  • Combinatorial therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Recruitment of Alpha5Beta1-Expressing Stromal Cells After Anti-VEGF Therapy

[0215]Sections of HT-29 human colorectal carcinoma xenografts that had been treated with anti-VEGF antibody B20-4.1 monotherapy in athymic mice were stained for anti-alpha5beta1 expression. Compared to a control group treated with a control antibody (anti-ragweed antibody) in this study, B20-4.1 monotherapy yielded a median time to endpoint (TTE) that corresponded to little or no activity. The tumors had been measured twice weekly for the duration of 58 days. Animals were euthanized when their tumors reached the endpoint volume of 1000 mm3 or on Day 58, whichever came first, and the (TTE) was calculated for each mouse. Treatment outcome had been determined from percent tumor growth delay (% TGD), defined as the percent increase in median TTE of treated versus control mice, with differences deemed significant at 0.01≦P≦0.05, and highly significant at P<0.01 using Logrank analysis. The median TTE value of the c...

example 2

Anti-Alpha5Beta1 Antibodies

[0217]Mice were injected with purified human alpha5beta1 (Chemicon CC1027). Plasmacytoma cells expressing anti-alpha5beta1 antibodies were isolated and transformed into hybridoma cell lines. Two hybridoma cell lines designated 7H5.4.2.8 and 7H12.5.1.4 were deposited with the ATCC. See above. The antibody produced from the 7H5.4.2.8 hybridoma is a mIgG2a Kappa antibody (also referred to herein as the “7H5 antibody”). The antibody produced from the 7H12.5.1.4 hybridoma is a mIgG2b Kappa antibody (also referred to herein as the “7H12 antibody”).

example 3

HUVEC Direct Binding Assay

[0218]Tissue cultures containing growing human umbilical vein endothelial cells (HUVEC) were washed twice with PBS. The cells were detached from the culture flask with 3-4 ml of a 5 mM EDTA / PBS solution. Fresh culture media was added to the cells and mixed. An aliquot of the cells in the mixture was counted. Cells were centrifuged and washed with wash buffer (50 mM Tris, 150 mM NaCl, pH7.5) one time. The cell concentration was adjusted so that the cells could be seeded at 25 ul per well onto 96-well MSD high binding plates at 25,000 cells / well or 4,000 cells / well on a 384 well plate (Cat #L11XB-1 or #L11XB-2, respectively, Meso Scale Diagnostics, LLC). The cells were incubated 1 hour at room temperature on the plate to allow capture. To block the well, 25 ul of stock buffer (30% fetal bovine serum (FBS) in TBS (50 mM Tris, 150 mM NaCl)+1 mM CaCl2 / 1 mM MgCl2, pH7.5) was added to the well and incubated at room temperature to for 30 minutes to 1 hour.

[0219]Ant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
molecular massaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and / or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and / or inhibited vascular permeability, including in abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.BACKGROUND OF THE INVENTION[0002]The important role of VEGF-A in pathological and non-pathological angiogenesis is well established. Administration of VEGF in in vivo models induces a potent angiogenic response (Plouet, J et al., (1989) EMBO J. 8:3801-3808; Leung, D. W., et al., (1989) Science 246:1306-1309). Loss of a single VEGF-A allele gave rise to an embryonic lethality in mice (Carmeliet, P., et al., (1996) Nature 380:435-439; Ferrara, N et al., (1996) N...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/28C07H21/00C12N15/63C12N5/00G01N33/53A61P35/00A61P37/00A61P27/02
CPCA61K2039/505A61K2039/507C07K16/22C07K16/2842C07K2317/73A61K51/1093C07K2317/92G01N33/74A61K39/3955A61K45/06C07K2317/76A61P1/04A61P11/00A61P13/12A61P15/00A61P17/00A61P17/02A61P17/06A61P19/02A61P19/06A61P25/00A61P25/06A61P25/08A61P27/02A61P27/06A61P29/00A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P35/02A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00A61P5/14A61P7/00A61P7/04A61P7/06A61P9/00A61P9/06A61P9/10C07K16/00A61K39/395
Inventor CHUNTHARAPAI, ANANPLOWMAN, GREGORY D.TESSIER-LAVIGNE, MARCWU, YANYE, WEILAN
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com